Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 495.00
Change Today +12.20 / 2.53%
Volume 12.4K
As of 8:33 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

exalenz bioscience ltd (EXEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/30/14 - $1,555
52 Week Low
04/8/15 - $470.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

exalenz bioscience ltd (EXEN) Related Businessweek News

No Related Businessweek News Found

exalenz bioscience ltd (EXEN) Details

Exalenz Bioscience Ltd. develops and commercializes breath test-based point-of-care disease management systems for gastrointestinal and liver disorders in Israel and internationally. It offers BreathID Hp, a urea breath test for diagnosing H. pylori infection; and for post-treatment monitoring of H. pylori infection in adults in the areas of primary care, gastric distress, bariatric surgery, and emergency room. The company is based in Modiin, Israel.

exalenz bioscience ltd (EXEN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 835.0K
Chief Financial Officer
Total Annual Compensation: 571.0K
Chief Operating Officer and General Manager
Total Annual Compensation: 633.0K
Vice President of Marketing and Business Deve...
Total Annual Compensation: 380.0K
Vice President of Sales
Total Annual Compensation: 324.0K
Compensation as of Fiscal Year 2013.

exalenz bioscience ltd (EXEN) Key Developments

Exalenz Bioscience Ltd, Annual General Meeting, Apr 16, 2015

Exalenz Bioscience Ltd, Annual General Meeting, Apr 16, 2015., at 10:00 Israel Standard Time.

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Dec 18, 2014

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Dec 18, 2014., at 10:00 Israel Standard Time.

Exalenz Bioscience Launches Pivotal Study of Breath-Based Test to Diagnose Clinically Significant Portal Hypertension

Exalenz Bioscience announced the start of a pivotal study investigating the potential of its BreathID(R) test as a non-invasive tool to diagnose Clinically Significant Portal Hypertension (CSPH), the most common complication of cirrhosis that accounts for significant morbidity and mortality in patients with advanced liver disease. The multinational study will compare the patient-friendly BreathID test to Hepatic Venous Pressure Gradient (HVPG). During the 200-patient first stage of the study, medical centers in Europe and the United States will recruit patients with chronic liver disease. Data collected during this stage will be used to build the index algorithm to compare the BreathID test with HVPG. During the second stage of the study, expected to start in 2016, investigators will verify the algorithm. Following completion of the pivotal study, Exalenz plans to submit data to the U.S. Food and Drug Administration (FDA) for PMA approval. Hepatic portal vein hypertension is currently diagnosed by measuring HVPG (Hepatic Venous Pressure Gradient), an invasive and expensive test that requires local anesthesia and the use of contrast material that may harm the kidneys, and exposes the patient to radiation. In addition, the test requires a high degree of skill, time and resources that are not available in most medical centers. Exalenz believes that the BreathID test will be a non-invasive, rapid, safe and significantly less expensive alternative test for this large market, estimated by the company to be approximately $100 million. Since the cost and complexities of currently available modalities to detect CSPH could be limiting the identification of many patients with this serious condition, Exalenz believes that the availability of a more convenient breath-based test could eventually increase the overall size of the market. The company plans to launch clinical studies for the diagnosis and monitoring of additional liver indications including NASH (non-alcoholic steateohepatitis), HCC (hepatocellular carcinoma) and ALF (acute liver failure). These will be achieved in part through partnering with companies developing therapies for these diseases.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEN:IT 495.00 +12.20

EXEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EXEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation EXEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXALENZ BIOSCIENCE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at